A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma-Reference-Cited by-同舟云学术

A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma

Published:2007-01 Issue:1 Volume:48 Page:39-45
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Vose Julie M.,Panwalkar Amit,Belanger Robert,Coiffier Bertrand,Baccarani Michele,Gregory Stephanie A.,Facon Thierry,Fanin Renato,Caballero Dolores,Ben-Yehuda Dina,Giles Francis

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428190600909578

Reference23 articles.

1. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

2. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

3. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.

4. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma.

5. Treatment of myeloma

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enantioselective Synthesis of β-l-5-[(E)-2-Bromovinyl)-1-((2S,4S)-2-(hydroxymethyl)-1,3-(dioxolane-4-yl) Uracil)] (l-BHDU) via Chiral Pure l-Dioxolane;The Journal of Organic Chemistry;2024-06-20

2. Quantum Mechanical Study of the Covalent Bonding of Troxacitabine with Functionalized Carbon Nanotubes;Moscow University Chemistry Bulletin;2021-07

3. Nucleophilic Cyclization/Electrophilic Substitution of (2,2-Dialkoxyethyl)ureas: Highly Regioselective Access to Novel 4-(Het)arylimidazolidinones and Benzo[d][1,3]diazepinones;Synthesis;2020-06-10

4. Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs;Chemical Reviews;2016-11-23

5. Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2014-08